Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around
Principal Investigator
by Shirin Attarian

Description

Summary

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.

Official Title

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Details

Keywords

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8, Carcinoma, Nasopharyngeal Carcinoma, Nivolumab, Ipilimumab, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, nivolumab, ipilimumab, nivolumab, ipilimumab, cabozantinib

Eligibility

Locations

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care accepting new patients
    Irvine California 92612 United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • USC Norris Oncology/Hematology-Newport Beach accepting new patients
    Newport Beach California 92663 United States

Lead Scientist at UC Irvine

  • Shirin Attarian
    Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 12 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT05904080
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 50 study participants
Last Updated